Our Deals
Deals
Gentris acquired by Cancer Genetics July 21, 2014
Overview
Cancer Genetics, Inc., an emerging leader in DNA-based cancer diagnostics focused on developing genomic-based oncology tests and services, announced the signing of a definitive agreement to acquire privately held Gentris Corporation, a global provider of clinical pharmacogenomics solutions, next-generation sequencing, and biomarker testing.
Gentris provides genomic testing and pharmacogenomics services to half of the top ten biopharma companies globally and has participated and performed genomic analysis for over 1,000 clinical trials.
The company has operations in Raleigh (Research Triangle Park), North Carolina and Shanghai, China in state-of-the-art GLP, CLIA, and FDA-compliant facilities.
Significance
Cancer Genetics will now be positioned to provide global services for genomic and biomarker testing for biotech and pharmaceutical companies by leveraging both its unique tests and comprehensive oncology services.
Crosstree’s Role
Crosstree Capital Partners served as exclusive financial advisor to Gentris.